<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>[REDACTED] Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                            <td>Tuna fish (substance)</td>
                            <td/>
                            <td/>
                            <td>[REDACTED]</td>
                </tr>
                <tr ID="AlertOBS-1001">
                            <td>sulfite</td>
                            <td/>
                            <td/>
                            <td>[REDACTED]</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1002">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>EXTENDED FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>EXTENDED FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>LDH</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Hepatic function panel</td>
				</tr>
				<tr ID="CarePlanRef-1007">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Vitamin B12 and Folate panel</td>
				</tr>
				<tr ID="CarePlanRef-1008">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1009">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Vitamin D, 1,25 (OH)2, total</td>
				</tr>
				<tr ID="CarePlanRef-1010">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Ferritin</td>
				</tr>
				<tr ID="CarePlanRef-1011">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Iron, TIBC, %SAT</td>
				</tr>
				<tr ID="CarePlanRef-1012">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>Renal function panel</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>EXTENDED FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1013">
							<td>[REDACTED]</td>
							<td>Breast cancer, female</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1014">
							<td>[REDACTED]</td>
							<td>Breast cancer, female</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1015">
							<td>[REDACTED]</td>
							<td>Osteoporosis</td>						
					</tr>
					<tr ID="EncounterDiagnosisRef-1016">
							<td>[REDACTED]</td>
							<td>Vitamin D deficiency (disorder)</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1017">
							<td/>
							<td>Umeclidinium-Vilanterol Inhaler 62.5 mcg-25 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1018">
							<td/>
							<td>Pravastatin Sodium Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1019">
							<td/>
							<td>Albuterol HFA Inhaler 90 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1020">
							<td/>
							<td>Fluticasone Nasal Spray 50 mcg/actuation </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1021">
							<td/>
							<td>bupropion Oral SR 12 hr Tab </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1022">
							<td/>
							<td>Cholecalciferol Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1023">
							<td/>
							<td>Levothyroxine Oral </td>
							<td/>
							<td> </td>
							<td/>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1024">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1025">
							<td>[REDACTED]</td>
							<td>100 ML zoledronic acid 0.05 MG/ML Injection [Reclast] </td>
							<td>intravenously</td>
							<td>5.0 mg</td>
							<td>once</td>
							<td>Flush line after infusion with 10 mL NS.</td>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1026">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1027">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1028">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1029">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1030">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1031">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1032">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1033">
							<td>[REDACTED]</td>
							<td>hydrochlorothiazide 12.5 MG / valsartan 80 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tab</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1034">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1035">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1036">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1037">
							<td>[REDACTED]</td>
							<td>Letrozole Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1038">
						<td>BMI 30+ - obesity</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1039">
						<td>UTI</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1040">
						<td>Breast cancer, female</td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1041">
						<td>Estrogen receptor positive status [ER+] </td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1042">
						<td>Breast cancer, female</td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1043">
						<td>High cholesterol</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1044">
						<td>Lymphedema (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1045">
						<td>Postmastectomy lymphedema syndrome (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1046">
						<td>Essential HTN</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1047">
						<td>Vitamin D deficiency (disorder)</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1048">
						<td>Estrogen receptor positive status [ER+] </td>
						<td>Active</td>
						<td>[REDACTED]</td>
				</tr>
				<tr ID="ProblemOBS-1049">
						<td>Osteoporosis</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="VitalSignsRef-1050">
						<td>[REDACTED]</td>
						<td>
							Body Temperature
							
						</td>
						<td>97.10</td>
				</tr>
				<tr ID="VitalSignsRef-1051">
						<td>[REDACTED]</td>
						<td>
							Heart Beat
							
						</td>
						<td>78.00</td>
				</tr>
				<tr ID="VitalSignsRef-1052">
						<td>[REDACTED]</td>
						<td>
							Respiratory Rate
							
						</td>
						<td>16.00</td>
				</tr>
				<tr ID="VitalSignsRef-1053">
						<td>[REDACTED]</td>
						<td>
							Oxygen Saturation
							
						</td>
						<td>94.00</td>
				</tr>
				<tr ID="VitalSignsRef-1054">
						<td>[REDACTED]</td>
						<td>
							BSA
							
						</td>
						<td>1.94</td>
				</tr>
				<tr ID="VitalSignsRef-1055">
						<td>[REDACTED]</td>
						<td>
							Pain Scale
							
						</td>
						<td>0.00</td>
				</tr>
				<tr ID="VitalSignsRef-1056">
						<td>[REDACTED]</td>
						<td>
							Weight
							
						</td>
						<td>207.20</td>
				</tr>
				<tr ID="VitalSignsRef-1057">
						<td>[REDACTED]</td>
						<td>
							Height
							
						</td>
						<td>62.00</td>
				</tr>
				<tr ID="VitalSignsRef-1058">
						<td>[REDACTED]</td>
						<td>
							BMI
							
						</td>
						<td>37.90</td>
				</tr>
				<tr ID="VitalSignsRef-1059">
						<td>[REDACTED]</td>
						<td>
							Intravascular Systolic
							
						</td>
						<td>127</td>
				</tr>
				<tr ID="VitalSignsRef-1060">
						<td>[REDACTED]</td>
						<td>
							Intravascular Diastolic
							
						</td>
						<td>87</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>[REDACTED]. <br/>Suite 210<br/>[REDACTED]

<br/>
<br/>Phone: [REDACTED] Fax: [REDACTED]


<br/>


<br/>Patient Name: [REDACTED]

<br/>Date of Birth: [REDACTED]

<br/>Medical Record #: [REDACTED]

<br/>Attending Physician: [REDACTED],  MD

<br/>Location: [REDACTED]

<br/>Referring Physician: [REDACTED] NPFP

<br/>


<br/>Follow-Up

<br/>Date of Visit: [REDACTED]

<br/>
<br/><p>Reason for OV [REDACTED]</p>Ongoing f/up b/l Breast cancer: <br/>L-Breast pT2 N0(i+)/ stage IIa vs IIb; <br/>R-Breast: pT2 N0 / stage IIa<br/>Hospitalized for pneumonia in fall of 2022<br/>So far [REDACTED]<br/>Review of the labs ([REDACTED]): unremarkable including tumor markers<br/>

<br/>History of Present Illness

<br/>This is a pleasant [REDACTED] female diagnosed with b/l breast cancer. She found a palpable mass in [REDACTED] and [REDACTED] the diagnostic bilateral digital breast tomosynthesis mammogram disclosed: <br/>i- dominant mass solid by ultrasound L-breast superior lateral quadrant 2.5 cm highly suspicious for malignancy. <br/>ii- Architectural distortion 12 o'clock position middle third right breast highly suspicious for malignancy.  Subsequently had bilateral breast biopsy [REDACTED], pathology disclosed <br/>R-breast: Invasive lobular carcinoma, grade 1/3, ER/PR+, Her2 neu negative.  <br/>L-breast: Invasive carcinoma with mixed ductal and lobular features, grade 1/3, ER/PR+, Her2 neu negative.<br/>[REDACTED] - CAT scan of the chest, abdomen and pelvis showed 2.6 cm irregular mass in the left breast consistent with primary breast malignancy.  There was no evidence of metastatic disease in the chest, abdomen and pelvis.  Bilateral renal cysts.<br/>She completed 2 cycles of Verzenio/Abemaciclib +Letrozole in neoadjuvant setting, followed by b/l radical mastectomy [REDACTED] without reconstruction.<br/>Pathology showed:<br/>Left breast: well differentiated invasive lobular carcinoma, ER/PR+, Her2 negative; pT2 pN0(i+)<br/>Right breast: moderately differentiated invasive lobular carcinoma, ER/PR+, Her2 negative; pT2 pN0<br/>[REDACTED]: Oncotype RS 11<br/>[REDACTED]: Breast Cancer Index shows benefit of extended endocrine therapy.<br/>She  continuous adjuvant Letrozole.<br/>OV [REDACTED]<br/>[REDACTED] - She continues to complain of worsening lymphedema left chest wall, initially required repeated drainage by the surgeon continues follow up with [REDACTED]. Gaining weight but overall feeling well. Continues to have some menopausal symptoms including hair thinning while on Letrozole, but tolerating well otherwise. <br/>She had recent hospitalization for bacterial pneumonia, still recovering followed by [REDACTED] (Pulmonology).<br/>OV [REDACTED]<br/>Ongoing f/up b/l Breast cancer: <br/>L-Breast pT2 N0(i+)/ stage IIa vs IIb; <br/>R-Breast: pT2 N0 / stage IIa<br/>She recovered from recent hospitalization for pneumonia<br/>Continues on letrozole;, so far [REDACTED]<br/>- Review of DEXA scan: [REDACTED]: osteporosis<br/>- CT chest: [REDACTED]: No focal pulmonary consolidation. Moderate emphysematous change with pleural parenchymal scarring.<br/>

<br/>Medical History<br/>-. Breast cancer, L breast pT2 N0(i+) - stage IIa vs IIb<br/>-. Breast cancer, R female pT2 N0 - stage IIa<br/>-. Estrogen receptor positive status [ER+]<br/>-. Postmastectomy lymphedema syndrome <br/>-. Vitamin D deficiency <br/>-. Essential HTN<br/>-. High cholesterol<br/>-. UTI

<br/>


<br/>Surgical History<br/> [REDACTED], Procedure: Mastectomy extended radical bilateral

<br/>


<br/>Medications<br/> Albuterol HFA Inhaler 90 mcg/actuation 90 mcg/actuation HFA aerosol inhaler, <br/>Anoro Ellipta (Umeclidinium-Vilanterol Inhaler 62.5 mcg-25 mcg/actuation) 62.5-25 mcg/actuation blister with device, <br/>Bupropion (SR) Oral ER Tab,<br/>Alendronate Oral (Weekly) 70 mg tablet 
1 tablet po/wk; sit upright for 60 minutes after
, <br/>Letrozole Oral 2.5 mg capsule 
1 capsule orally daily. , <br/>Valsartan-Hydrochlorothiazide Oral 80 mg-12.5 mg tablet 
1 tab/po daily. , <br/>Fluticasone Nasal Spray 50 mcg/actuation 50 mcg/actuation spray, suspension, <br/>Levothyroxine Oral 150 mcg tablet, <br/>Pravastatin Sodium Oral 40 mg tablet, <br/>Vitamin D (Cholecalciferol Oral) 1,250 mcg (50,000 unit) capsule

<br/>

<br/>Smoking History<br/>


<br/>Smoking Tobacco : Current every day smoker; <br/>Smokeless Tobacco : none found; Vaping : none found

<br/>


<br/>Social History

<br/>

<br/>Family History<br/>    

<br/>


<br/>Allergies<br/> Tuna fish (substance)<br/>sulfite

<br/>


<br/>Review of Systems

<br/>back pain 7/10<br/>Constitutional: Denies fever, weight loss, fatigue<br/>Eyes: Denies visual changes<br/>ENT/Mouth: Denies hearing problems, oral problems<br/>Cardiovascular: Denies chest pain, palpitations<br/>Respiratory: Denies shortness of breath, cough<br/>Breast: Denies pain, masses, discharge<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence<br/>Gynecological: Denies vaginal discharge, abnormal vaginal bleeding<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain<br/>Skin: Denies rashes, itchiness, ulcers<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness <br/>Psychiatric: Denies depression, anxiety<br/>Hematologic/Lymphatic: Denies other bleeding, bruising, swollen lymph nodes

<br/>


<br/>Physical Examination

<br/>Blood pressure: 127/87, R arm, Regular, Pulse: 78, Temperature: 97.1 F, Respirations: 16, O2 sat: 94%, At Rest, Room Air, Pain Scale: 0, Height: 62 in, Weight: 207.2 lb, BSA: 1.94, BMI: 37.9 kg/m2

<br/>General:  Alert &amp; oriented, no acute distress<br/>Skin: Normal<br/>HEENT:  Pupils equal, round. Oral cavity, oropharynx clear<br/>Neck:  Supple, no mass<br/>Breast: healed b/l mastectomy. left side chest swelling, no erythema, no lymphadenopathy<br/>Lungs: Clear to auscultation, bilaterally<br/>Heart: Regular rate and rhythm, no murmurs, rubs or gallops<br/>Back: Nontender<br/>Abdomen: Soft, nontender, nondistended, no masses palpable, no hepatosplenomegaly, normal bowel sounds<br/>Genitourinary: Deferred<br/>Extremities: No clubbing, cyanosis, or edema

<br/>


<br/>Laboratory<br/>
<br/>CBC<br/>([REDACTED]) WBC x 10^3/uL : 6.2; RBC x 10^6/uL : 4.41; HGB g/dL : 13.6; HCT % : 40.7; MCV fL : 92.3; MCH pg : 30.8; MCHC g/dL : 33.4; RDW % : 13.8; PLT x 10^3/uL : 255; MPV fL : 10.1; Neu % : 57.4; LY % : 28.5; MO % : 10.1; EO % : 3.5; BA % : 0.5; NEU #, cells/uL : 3559; LY #, cells/uL : 1767; MO #, cells/uL : 626; EO #, cells/uL : 217; BA #, cells/uL : 31

<br/>
<br/>Manual Differential<br/>([REDACTED]) NRBC, #/100 wbc : DNR; NRBC, absolute, cells/uL (M) cells/uL : DNR; Band % : DNR; Promyelocyte % : DNR; Bands, absolute, cells/uL : DNR; Promyelocyte, absolute, cells/uL : DNR

<br/>CMP<br/>([REDACTED]) Glucose mg/dL : 99; BUN mg/dL : 24; Creatinine mg/dL : 1.09 (H); BUN/Creatinine ratio : 22; Sodium mmol/L : 138; Potassium mmol/L : 4.5; Chloride mmol/L : 107; CO2 mmol/L : 25; Calcium mg/dL : 9.3; Albumin g/dL : 4.0; Total protein g/dL : 6.8; Globulin g/dL : 2.8; A/G ratio : 1.4; Bilirubin, total mg/dL : 0.6; [REDACTED], direct mg/dL : 0.1; Bilirubin, indirect mg/dL : 0.5; Alkaline phosphatase U/L : 76; AST/SGOT U/L : 20; ALT/SGPT U/L : 21; Phosphorus mg/dL : 2.9; Vitamin D, 25-hydroxy ng/mL : 63; C-reactive protein (CRP), cardiac, mg/L : 2.6

<br/>Tumor Markers<br/>([REDACTED]) CEA ng/mL : &lt;2.0; CA 27-29 U/mL : 27; CA 125 U/mL : 11

<br/>Anemia Labs<br/>([REDACTED]) Iron / FE ug/dL : 119; TIBC ug/dL : 295; Ferritin ng/mL : 175; Vitamin B12 pg/mL : 277

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>Other<br/>([REDACTED]) CBC Comments : DNR; ABSOLUTE BLASTS : DNR; ABSOLUTE METAMYELOCYTES : DNR; ABSOLUTE MYELOCYTES : DNR; BLASTS : DNR; METAMYELOCYTES : DNR; MYELOCYTES : DNR; REACTIVE LYMPHOCYTES : DNR; Enhanced PDF Report ZL908869B-1 : See attached; EGFR : 52 (L); % SATURATION : 40


<br/>
<br/>Radiology<br/>


<br/>
<br/>


<br/>


<br/>Pathology<br/>   
[REDACTED] - b/l mastectomy

<br/>

<br/>L-breast mastectomy: Invasive ductal carcinoma.  Well-differentiated 1/3.  

<br/>Tumor measures 3.4 cm in greatest dimension.  Ductal carcinoma in situ 1% of the tumor volume.  Low nuclear grade.  Lymphovascular invasion is not identified.  

<br/>Tumor is 2 mm from the deep margin, all other margins are over 1 cm.  

<br/>ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC.

<br/>Number of positive lymph nodes N1(+) out of 3.  

<br/>Size of largest metastatic focus: Less than &lt;1 mm, isolated tumor cells only. 

<br/>Extranodal tumor deposit identified: 0.7 cm.  

<br/>AJCC pTNM classification: pT2 pN0(i+); [concern that the staging is not correct because Micro-metastases are defined as clusters of cancer cells that are between 0.2 mm and 2 mm in diameter. Any smaller clusters are called isolated tumor cells); therefore the correct definition is pN1 not pN0(i+).]


<br/>As far as the extranodal extention this should be reported to the surgeon

<br/>


<br/>R-breast: Invasive lobular carcinoma, measuring 2.2 cm in greatest dimension.  Nottingham histologic grade 6/9, moderately differentiated.  

<br/>Size of invasive tumor 2.2 cm.  0 out of 3 positive lymph nodes.  

<br/>Lymphovascular invasion present.  

<br/>ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC.  

<br/>AJCC pTNM: pT2 pN0.
<br/>
[REDACTED] - b/l need biopsy<br/>
<br/>
<br/>R-breast: Invasive lobular carcinoma,  grade 1 out of 3.  Greatest dimension of largest invasive focus 0.9 cm.  Ductal carcinoma in situ, LCIS not identified.  LVI:not identified.  Microcalcifications are present.  ER(+)/PR(+), HER-2 no overexpression.

<br/>


<br/>L-breast: Invasive carcinoma with mixed ductal and lobular features, histologic grade 1 out of 3.  Greatest dimension of largest invasive focus 1.1 cm at least.  DCIS and LCIS not identified; LVI and microcalcifications not identified.  ER(+)/51-90%, HER-2 no overexpression.<br/>Impression/Discussion<br/>This is a pleasant [REDACTED] female patient diagnosed with bilateral breast cancer. Invasive lobular carcinoma s/p 2 cycles of neoadjuvant Verzenio/Abemaciclib +Letrozole followed by b/l radical mastectomy without reconstruction.<br/>1.- Pathology Bilateral breast carcinoma s/p bilateral mastectomy staged as:<br/>L-breast: pT2pN0(i+); stage IIa vs IIb since ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC<br/>(the difference between isolated tumor cells (ITCs) and micrometastases, is that the former is &lt; 0.2 mm while the latter is between 0.2-2.0 mm; this tumor is at 1 mm which qualifies <br/>R-breast: pT2 N0 M0 &gt;&gt; stage IIa<br/>2.-  Bilateral chest wall lymphedema L&gt;R, persistent in spite of 4 draining procedures.<br/>She will discuss with [REDACTED] at her upcoming visit<br/>3.-  stable condition and tumor markers normal. She wil;l continue lwetrozole and we will continue monitoring<br/>4- Obesity stage 2<br/>5- PS ECOG scale 0<br/>Plan/Recommendations<br/>.- Continue Letrozole<br/>.- Repeat labs prior to next visit: CBC, CMP, CA 27.29, Vit B12, folate, Vit D, ferritin, iron<br/>CBC With Diff and Plt ([REDACTED])<br/>Ferritin ([REDACTED])<br/>Hepatic function panel ([REDACTED])<br/>Iron, TIBC, %SAT ([REDACTED])<br/>LDH ([REDACTED])<br/>Renal function panel ([REDACTED])<br/>RTC ([REDACTED])<br/>Vitamin B12 and Folate panel ([REDACTED])<br/>Vitamin D, 1,25 (OH)2, total (11/16.- Continue follow up with [REDACTED]<br/>.- Continue follow up with [REDACTED] (Pulmonology)<br/>.- Continue follow up with PCP and continue routine screening as per national guidelines.<br/>.- Gradually improve physical health<br/>.- RTC [REDACTED]<br/>Diagnosis<br/>Breast cancer, L-breast pT2 N0(i+) - stage IIa vs IIb /ER(+)/51-90%, PR(+)/51-90%, HER-2 0 <br/>Breast cancer, R-female pT2 N0 - stage IIa /ER(+)/51-90%, PR(+)/51-90%, HER-2 0, by IHC.  <br/>Postmastectomy lymphedema syndrome <br/>Obesity<br/>Vitamin D deficiency (disorder)<br/>High cholesterol<br/>Essential HTN<br/>UTI<br/>PS ECOG scale 0<br/>CC<br/>[REDACTED] M.D.<br/>[REDACTED] (Referring) <br/>Signature<br/>Note created by [REDACTED] MD, Physician,    <br/>Total duration of OV about 40 min
<br/>Electronically signed by [REDACTED] MD [REDACTED] 02:49 PM PST 
		        </p>
		      </li></ul>
</div><br/><br/>
</body></html>